<DOC>
	<DOCNO>NCT00286897</DOCNO>
	<brief_summary>Patients randomise receive either placebo study drug period 30 week , addition standard Parkinsonian medication . During first 8 week , patient 's levodopa dos may adjust necessary investigator . For remainder 22 week , medication keep stable . Patients required attend clinic twice screen period 8 time treatment period . They require complete home diary record motor function . In addition , doctor ass Parkinson 's disease clinic visit . There also blood draw safety pharmacokinetic pharmacogenomics evaluation . Following treatment assessment period , return clinic one month later follow .</brief_summary>
	<brief_title>The Efficacy , Safety Tolerability E2007 Levodopa Treated Parkinson 's Disease Patients With Motor Fluctuations</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Male female patient idiopathic PD fulfilling ( UK ) Parkinson 's disease Society Brain Bank diagnostic criterion , good response levodopa . 2 . Patients must diagnose idiopathic PD &gt; = 30 year age . 3 . Patients must predictable motor fluctuation wear OFF type presence least 2 hour OFF time wake day ( exclude morning OFF time ) evidence diary card complete screen confirmed diary data collect baseline visit . 4 . Before patient randomise must able show able accurately complete diary card . During diarytraining period initial screen visit must diary evidence least one transition OFF ON ON OFF patient must show 75 % concordance Investigator 's completion diary card . 5 . Patients must rate IIIV Hoehn &amp; Yahr scale OFF state . 6 . Patients must take optimised levodopa therapy ( accord investigator 's opinion ) least 3 time waking day ( include bedtime/night time dose ) maximum 8 dos daily ( include bedtime/night time dose ) . 7 . Patients treat dopamine agonist , COMT inhibitor MAOB inhibitor antiPD drug must optimise stable dos least 4 week prior initial screen visit must remain stable throughout study . Only levodopa dosage adjust downwards first 8 week doubleblind treatment phase . 8 . In Investigator 's opinion patient must able distinguish motor state absence presence troublesome nontroublesome dyskinesia . 9 . In Investigator 's opinion patient able complete study include completion home diary card capable give full write informed consent . EXCLUSION CRITERIA : 1 . Pregnant lactating woman . 2 . Women child bear potential unless infertile ( include surgically sterile ) practice effective contraception ( e.g. , abstinence , IUD barrier method plus hormonal method ) . These patient must negative serum BHCG test initial screen visit ( Visit 1 ) , negative urine pregnancy test Baseline visit ( Visit 3 ) . These patient must also willing remain current form contraception duration study . Postmenopausal woman may recruit must amenorrhoeic least 1 year consider nonchild bear potential determined investigator . 3 . Fertile men willing use reliable contraception fertile men partner willing use reliable contraception . 4 . Patients past present history drug alcohol abuse per DSM IV criterion . 5 . Patients past ( within one year ) present history psychotic symptom require antipsychotic treatment . Patients may take antidepressant medication , however dose must stable 4 week prior baseline visit . Use antipsychotic medication include clozapine quetiapine prohibit even indication movement disorder . 6 . Patients past ( within one year ) present history suicidal ideation suicide attempt . 7 . Patients unstable abnormality hepatic , renal , cardiovascular , respiratory , gastrointestinal , haematological , endocrine metabolic system might complicate assessment tolerability study medication . 8 . Patients significantly elevate liver enzyme ( abnormal bilirubin serum transaminase level 1.5 time upper normal limit ) . 9 . Patients current prior treatment ( within 4 week prior baseline visit ) medication know induce enzyme cytochrome P450 3A4 . 10 . Current prior treatment ( within 4 week prior baseline visit ) tolcapone , methyldopa , budipine , reserpine , seroquel intermittent use either liquid form levodopa subcutaneous apomorphine . 11 . Patients previous stereotactic surgery ( eg pallidotomy ) Parkinson 's disease plan stereotactic surgery study period . 12 . Patients receive plan ( next 6 month ) deep brain stimulation . 13 . Patients receive investigational product within 4 week prior screen visit patient participate previous study E2007 . 14 . Patients clinically significant cognitive impairment ( MMSE &lt; 24 /or fulfil DSM IV criterion dementia due Parkinson 's disease ) . 15 . Patients condition affect peripheral central sensory system unless related Parkinson 's disease ( mild sensory pain syndrome limit OFF period ) could interfere evaluation symptom cause study drug . 16 . Patients condition would make patient , opinion Investigator , unsuitable study .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>